DareonTM-5: An open-label Phase II trial of BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas

Authors
Category Primary study
JournalMOLECULAR CANCER THERAPEUTICS
Year 2023
This article has no abstract
Epistemonikos ID: c49da04644a91475149b160e96426b8bd0c0d3a3
First added on: Apr 29, 2024